A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pfizer
Tizona Therapeutics, Inc
UNC Lineberger Comprehensive Cancer Center
Eli Lilly and Company
Novartis
TILT Biotherapeutics Ltd.
Institute of Cancer Research, United Kingdom
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Trishula Therapeutics, Inc.
Compugen Ltd
Thomas Jefferson University
Jonsson Comprehensive Cancer Center
Inhibrx Biosciences, Inc
National Cancer Institute (NCI)
Celldex Therapeutics
University of California, San Francisco
R-Pharm
Corvus Pharmaceuticals, Inc.
Memorial Sloan Kettering Cancer Center
Cantargia AB
M.D. Anderson Cancer Center
Viralytics
Incyte Corporation
Syndax Pharmaceuticals
BioNTech SE
Pfizer